Generative AI is revolutionizing Drug-Target Interaction (DTI) prediction by automating drug design, improving binding accuracy, and accelerating discovery timelines. It replaces manual, trial-and-error methods with predictive, end-to-end pipelines. While challenges like interpretability and data quality persist, real-world case studies show its promise. GenAI is set to reshape pharma by making drug discovery faster, smarter, and more scalable.

In silico screening powered by Gen AI is transforming drug discovery by enabling rapid, cost-effective analysis of millions of compounds. Tools like Pitchworks’ Conversational Docking Assistant (CDA) streamline docking workflows, automate reporting, and enhance interpretability. With secure, compliant infrastructure, CDA reduces analysis time by 70%, supports HIPAA/FDA standards, and accelerates early-stage decision-making in pharma and biotech.